mRNA-CAR-T Descartes-08's Potential for Treating Myasthenia Gravis - CGTLive®
Cartesian Therapeutics' Descartes-08, an autologous BCMA-directed mRNA CAR-T therapy, showed deep remission in MG patients up to 12 months post-treatment at the ASGCT 27th Annual Meeting. The therapy, administered without lymphodepletion chemotherapy in an outpatient setting, demonstrated a strong safety profile with no cytokine release syndrome or neurotoxicity. Challenges included integrating different medical teams and COVID-19 affecting enrollment. Future plans include trials for systemic lupus and other autoimmune diseases, with an ongoing double-blind placebo-controlled trial in MG.
Highlighted Terms
Related News
Cartesian Therapeutics' Descartes-08, an autologous BCMA-directed mRNA CAR-T therapy, showed deep remission in MG patients up to 12 months post-treatment at the ASGCT 27th Annual Meeting. The therapy, administered without lymphodepletion chemotherapy in an outpatient setting, demonstrated a strong safety profile with no cytokine release syndrome or neurotoxicity. Challenges included integrating different medical teams and COVID-19 affecting enrollment. Future plans include trials for systemic lupus and other autoimmune diseases, with an ongoing double-blind placebo-controlled trial in MG.